Table of contents
August 2002 Vol 1 No 8
In this issue
p561 | doi:10.1038/nrd888
Editorial: New resources on the horizon
p563 | doi:10.1038/nrd889
Research Highlights
Sleep control: Regular as clockwork
p565 | doi:10.1038/nrd876
Anticancer drugs: Next in line?
p566 | doi:10.1038/nrd878
Stress-related disorders: Controlling emotion
p566 | doi:10.1038/nrd887
Viral infections: Exchange control
p567 | doi:10.1038/nrd880
Heat-shock proteins: TNF in hot shocker
p568 | doi:10.1038/nrd879
Anticancer drugs: Deadly cargo
p568 | doi:10.1038/nrd881
In brief
Allergy | Cardiovascular disease | Anticancer drugs | Nanotechnology
p569 | doi:10.1038/nrd882
Adrenoceptor pharmacology: How the ligand changed its spots
p569 | doi:10.1038/nrd885
Lead identification: Best with both worlds?
p570 | doi:10.1038/nrd877
News and Analysis
Patent watch
Electronic filing ready to go... | Hope for Genentech?
p570 | doi:10.1038/nrd883
From the analyst's couch
Value of novelty?
p571 | doi:10.1038/nrd884
Reviews
New tools and concepts for modern organic synthesis
Steven V. Ley & Ian R. Baxendale
p573 | doi:10.1038/nrd871
CDKS and CKIS: Molecular targets for tissue remodelling
Elizabeth G. Nabel
p587 | doi:10.1038/nrd869
The use of constitutively active GPCRs in drug discovery and functional genomics
Derek T. Chalmers & Dominic P. Behan
p599 | doi:10.1038/nrd872
Endogenous kynurenines as targets for drug discovery and development
Trevor W. Stone & L. Gail Darlington
p609 | doi:10.1038/nrd870
Drugs targeting the renin–angiotensin–aldosterone system
Mohammad Amin Zaman, Suzanne Oparil & David A. Calhoun
p621 | doi:10.1038/nrd873
Perspectives
Timeline
The emergence of the drug receptor theory
Andreas-Holger Maehle, Cay-Rüdiger Prüll & Robert F. Halliwell
p637 | doi:10.1038/nrd875
Opinion
Careers and Recruitment
Mass spectrometry in drug discovery and development
John Michnowicz
p651 | doi:10.1038/nrd886
